Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1

Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3mRVKSm
via IFTTT